Clinical trials: Tenecteplase
Hemorrhagic Transformation Stroke
Robot-Assisted Hematoma Evacuation With Intrahematoma Tenecteplase for Post-Reperfusion PH2 Hemorrhagic Transformation
The purpose of this phase I trial is to evaluate the safety and feasibility of robot-assisted stereotactic minimally invasive hematoma aspiration, followed when eligible by intrahematoma tenecteplase administration, in patients…
- Trial name
- REPORT (NCT07641998)
- Testing
- Robot-assisted stereotactic hematoma aspiration plus intrahematoma tenecteplase
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tiantan Hospital
Intracerebral Hemorrhage, Intracranial Hemorrhages
Tenecteplase (TNK) in the Treatment of Intracerebral Hemorrhage (ICH)
The overall purpose of this study is to look at the safety and effectiveness of administering Tenecteplase (TNK) into the brain bleed (hematoma) instead of another clot-dissolving drug known as recombinant tissue plasminogen…
- Conditions
- Intracerebral Hemorrhage, Intracranial Hemorrhages, Hemorrhagic Strokes
- Trial name
- TNK in ICH (NCT06696131)
- Testing
- TNK
- Volunteers
- 5 people
- Sponsor
- Gaurav Gupta, MD
Acute Ischemic Stroke, Intracranial Artery Occlusion
Intra-arterial TNK Following Endovascular Thrombectomy in Patients With Large Vessel Occlusion of Posterior Circulation
Rationale: Recently, one prospective multicenter RCT reported a potential beneficial effect of intra-arterial alteplase following successful endovascular thrombectomy (EVT) in patients with an acute intracranial large vessel…
- Conditions
- Acute Ischemic Stroke, Intracranial Artery Occlusion, Endovascular Thrombectomy
- Trial name
- NCT05684172
- Testing
- Tenecteplase, endovascular thrombectomy alone
- Where
- China
- Volunteers
- 208 people
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
Stroke
A Multicenter, Retrospective, Observational Cohort Study on Intravenous Thrombolysis Beyond the Time Window for Acute Ischemic Stroke
A multicenter, retrospective, observational cohort study on intravenous thrombolysis beyond the time window for acute ischemic stroke
- Trial name
- TRAILBLAZER (NCT07419997)
- Where
- China
- Volunteers
- 2,600 people
- Sponsor
- Xuanwu Hospital, Beijing
Acute Ischemic Stroke
Tenecteplase Compared to Alteplase for Patients With Large Vesel Oclusion Suspicion Before Thrombectomy
Background: The TNKCAT trial represents an innovative approach to optimize timely reperfusion in the Mothership and Drip-and-Ship scenarios.
- Trial name
- NCT05626972
- Testing
- Tenecteplase
- Where
- Spain
- Volunteers
- 500 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Stroke
CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase II
To explore the efficacy and safety of tenecteplase for acute ischemic stroke patients (onset time 4.5-24h) of large vessel occlusion using early combined CT/MR imaging outcomes
- Trial name
- CHABLIS-T II (NCT04516993)
- Testing
- Tenecteplase, The best treatment selected by local doctors(Aspirin, Recombinant Tissue Plasminogen Activator, Urokinase, Thrombectomy)
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Huashan Hospital
Ischemic Stroke
Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN)
This is a double-blind parallel arm randomized trial aimed to assess efficacy and safety of intravenous Tenecteplase compared to intravenous Alteplase in eligible patients who present with symptoms of acute ischemic stroke within…
- Trial name
- TALISMAN (NCT02180204)
- Testing
- Tenecteplase, Alteplase
- Where
- United States
- Sponsor
- Reza Behrouz, DO
Acute Distal Vessel Occlusion Stroke
Early Recanalization After Intravenous Thrombolysis With Tenecteplase Versus Alteplase in Distal Vessel Occlusion Strokes
The purpose of this monocentric retrospective study is to compare, in patients with acute distal vessel occlusion stroke, the early rates of successful recanalization in patients treated with Alteplase (ALT) versus Tenecteplase…
- Trial name
- DISTAL-IVT (NCT05635786)
- Testing
- Alteplase (0.9mg/kg), Tenecteplase (0.25mg/kg)
- Where
- France
- Volunteers
- 319 people
- Sponsor
- Centre Hospitalier Sud Francilien
Acute Ischemic Stroke
Tenecteplase in Acute Ischemic Stroke Under Different Transfer Models
This prospective, multicenter, observational cohort study aims to evaluate the safety and effectiveness of intravenous tenecteplase (rhTNK-tPA) in patients with acute ischemic stroke managed under different transfer models.
- Trial name
- NCT07897955
- Testing
- tenecteplase
- Where
- 6 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Fujian Medical University Union Hospital
Ischemic Stroke
Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis
The principle research question is: in patients with acute ischaemic stroke eligible for intravenous (IV) thrombolysis, is tenecteplase superior in efficacy to alteplase, based on functional outcome as assessed by modified Rankin…
- Trial name
- ATTEST2 (NCT02814409)
- Testing
- Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase, Intravenous Tenecteplase
- Where
- United Kingdom
- Volunteers
- 1,858 people
- Sponsor
- NHS Greater Glasgow and Clyde
Stroke, Acute, Thromboses, Intracranial
Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke
The proposed trial is a pragmatic, registry linked, prospective, randomized (1:1) controlled, open-label parallel group clinical trial with blinded endpoint assessment of 1600 patients to test if intravenous tenecteplase (0.25…
- Trial name
- AcT (NCT03889249)
- Testing
- Tenecteplase, Alteplase
- Where
- 22 sites in Canada
- Volunteers
- 1,600 people
- Sponsor
- University of Calgary
Acute Ischemic Stroke AIS, Stroke Acute
ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
This domain has a prospective, randomized, controlled, open-label, parallel group with blinded endpoint assessment (PROBE) design.
- Conditions
- Acute Ischemic Stroke AIS, Stroke Acute, Stroke, Acute, Stroke Ischemic
- Trial name
- ACT-WHEN (NCT06320431)
- Testing
- Tenecteplase
- Where
- 24 sites in Australia, Canada
- Volunteers
- 4,000 people
- Sponsor
- University of Calgary
Ischemic Stroke, Acute, Thrombolysis
Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion
The purpose of this study is to investigate the safety and efficacy of endovascular treatment with or without preceding intravenous Tenecteplase in patients with late-window (4.5-24 hours of symptom onset) acute ischemic stroke…
- Conditions
- Ischemic Stroke, Acute, Thrombolysis, Endovascular Treatment
- Trial name
- TNK-PLUS (NCT06221371)
- Testing
- Tenecteplase, direct EVT
- Where
- 21 sites in China
- Volunteers
- 391 people
- Sponsor
- Beijing Tiantan Hospital
Deep Intracerebral Hemorrhage (ICH)
Neuronavigation-assisted Stereotactic Puncture With Tenecteplase for Acute Intracerebral Hemorrhage
Background Minimally invasive puncture surgery followed by thrombolysis has been proven to be an effective approach for managing hypertensive intracerebral hemorrhage.
- Trial name
- NAS-TNK (NCT06868511)
- Testing
- Neuronavigation-assisted Stereotactic Minimally Invasive Puncture Combined with Tenecteplase, Standard medical treatment
- Where
- China
- Volunteers
- 732 people
- Sponsor
- Beijing Tiantan Hospital
Acute Ischemic Stroke
Tenecteplase for Late-Window Stroke Guided by DWI-FLAIR Mismatch
The goal of this clinical trial is to evaluate the efficacy and safety of tenecteplase administered 4.5-9 hours after stroke onset (defined as the time the patient was first found with symptoms, including wake-up stroke and…
- Trial name
- TRUST-MISMATCH (NCT07540416)
- Testing
- TNK-tPA, Aspirin
- Where
- China
- Volunteers
- 564 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Myocardial Infarction
STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction
This study aims at evaluating, in a proof of concept approach, the outcome of patients presenting with acute ST-elevation myocardial infarction within 3 hours of symptom onset in either a pre-hospital setting or community…
- Trial name
- NCT00623623
- Testing
- primary PCI, enoxaparin, catheterisation
- Where
- 201 sites in Austria, Belgium and 14 more
- Volunteers
- 1,899 people
- Sponsor
- Boehringer Ingelheim
Dysfunctional Hemodialysis Catheters
A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis Catheters
This was a Phase III, randomized, double-blind, placebo-controlled study conducted at 37 centers in the United States. 150 subjects ≥ 16 years of age who required hemodialysis (HD) and had a dysfunctional HD catheter were…
- Trial name
- TROPICS 3 (NCT00396032)
- Testing
- tenecteplase
- Volunteers
- 150 people
- Sponsor
- Genentech, Inc.
Acute Respiratory Distress Syndrome
Treatment of Acute Respiratory Distress Syndrome With Tenecteplase: A Dose Escalation Pilot Study
The pathogenesis of ARDS appears to be from damage to the alveolar-capillary barrier, which is composed of the microvascular endothelium and the alveolar epithelium. This damage may occur from direct or indirect lung injury.
- Trial name
- NCT00431379
- Testing
- Tenecteplase
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Acute Ischemic Stroke
Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ
A Phase Ⅲ, Multicenter, Prospective, Randomized, Open Label, Blinded-endpoint (PROBE) Controlled Trial of Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) for Injection Versus Alteplase for Acute Ischemic…
- Trial name
- TRACEⅡ (NCT04797013)
- Testing
- rt-PA, rhTNK-tPA
- Where
- 61 sites in China
- Volunteers
- 1,430 people
- Sponsor
- Beijing Tiantan Hospital
Intraventricular Hemorrhage
rhTNK-tPA Thrombolytic Removal of Intraventricular Hemorrhage
The purpose of this pilot study is to determine the safety and optimal dose of clot lysis with rhTNK-tPA for intraventricular hemorrhage, using stereotactic guidance for extraventricular drain placement.
- Trial name
- NCT06814964
- Testing
- Low dose group, Medium dose group, High dose group
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Beijing Tiantan Hospital